“The company expects cannabis net revenue for fiscal Q1 2024 to be largely similar to fiscal Q3 2023, with the geographical mix slightly weighted towards the international medical segment. For plant propagation, we expect to see a seasonally strong quarter as we reach our peak selling period. Furthermore, the company expects Adjusted Gross Margins to be consistent with fiscal Q3 2023 and expects to maintain our stated objective of a quarterly SG&A expense run rate below $30 million.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACB:
- Aurora Cannabis Announces Fiscal 2023 Third Quarter and Files Full Year Results
- Here’s What You Missed in Cannabis This Week
- Rising High: Exclusive talk with cannabis market research firm BDSA
- Taxes Prove Problematic for Canadian Cannabis Companies
- Rising High: Exclusive talk with financial services firm Safe Harbor